EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Turco Fabio, Gillessen Silke, Salfi Giuseppe, Kloots Iris S H, Slootbeek Peter H J, Mehra Niven, Labriola Matthew, George Daniel J, Broderick Amanda, Patrikidou Anna, Patry Hortense, Buttigliero Consuelo, Crespi Veronica, Uemura Hirotsugu, Fujita Kazutoshi, Utsumi Takanobu, Suzuki Hiroyoshi, Raggi Daniele, Basso Umberto, Morales-Barrera Rafael, Marmolejo Castaneda David, Sternberg Cora N, Guevara Daniela, Caffo Orazio, Procopio Giuseppe, Zivi Andrea, Merler Sara, Sorarù Mariella, Spratt Daniel E, C Barata Pedro, Messina Carlo, Ürün Yüksel, Bolek Hatice, Duràn Ignacio, Lavin Juan Diego Cacho, Martínez Chanzá Nieves, Horvath Lisa G, Mellor Rhiannon, Türkeri Levent, Soykök Merve Bengisu, Rossetti Sabrina, Cathomas Richard, Banna Giuseppe Luigi, Conteduca Vincenza, Ottaviano Margaret, Marandino Laura, Lin Hui-Ming, Tortola Luigi, Pereira Mestre Ricardo, Pedrani Martino
Аннотация
METHODS: Patients with EP mHSPC were defined as patients who had progression ≤6 months under ADT+docetaxel or ADT + ARPI or ≤9 months from ADT monotherapy start. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS).
RESULTS: Data from eligible patients treated between 2005 and 2023 were retrospectively collected. 201 (50%) patients received ADT monotherapy, while 124 (31%) and 76 (19%) received ADT+docetaxel and ADT + ARPI, respectively. 365 (91%) patients underwent first-line treatment for mCRPC-majority of the ADT monotherapy received ARPI (38%) or docetaxel (34%), whereas 69% of the ADT+docetaxel received ARPI and 62% of the ADT + ARPI received docetaxel. In the group of patients treated with ADT the median PFS was 6.8 months while the median OS was 26.4. In the group of patients treated with combination therapy the median PFS and OS was 4.9 and 18.6 months for patients who received docetaxel and 5.6 and 19.5 months for patients who received ARPI, respectively. Neither the first-line mCRPC treatment nor the genetic profiles were associated with survival outcomes.
CONCLUSIONS: The results of our study suggest that patients with EP mHSPC are characterized by poor outcomes regardless of the type of treatment received at progression. The optimal first-line mCRPC therapy to use in these patients remains a crucial unmet clinical need.